- Home
- WSBC vs CELC Comparison
WSBC vs CELC Comparison
Compare WSBC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSBC | CELC |
|---|---|---|
| Founded | 1870 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | WSBC | CELC |
|---|---|---|
| Price | $35.12 | $111.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $39.00 | ★ $100.13 |
| AVG Volume (30 Days) | 474.7K | ★ 760.1K |
| Earning Date | 01-27-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $903,813,000.00 | N/A |
| Revenue This Year | $41.92 | N/A |
| Revenue Next Year | $13.64 | N/A |
| P/E Ratio | $15.39 | ★ N/A |
| Revenue Growth | ★ 53.98 | N/A |
| 52 Week Low | $26.42 | $7.58 |
| 52 Week High | $37.18 | $120.32 |
Technical Indicators
Market Signals| Indicator | WSBC | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 56.49 |
| Support Level | $33.94 | $103.00 |
| Resistance Level | $35.41 | $120.32 |
| Average True Range (ATR) | 0.93 | 6.21 |
| MACD | -0.00 | 0.31 |
| Stochastic Oscillator | 50.56 | 55.33 |
Price Performance
Historical ComparisonAbout WSBC WesBanco Inc.
Wesbanco Inc is a bank holding company. Through its subsidiaries, it offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. The company's reportable segments are Community Banking, which derives key revenue, and Trust and Investment Services. The Community Banking segment offers various banking products and services through various delivery channels, including commercial demand, individual demand, and time deposit accounts; commercial, mortgage, and individual installment loans; and certain non-traditional offerings, such as insurance and securities brokerage services.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.